Full-Time
No salary listed
Mid, Senior
Philadelphia, PA, USA + 2 more
More locations: Princeton, NJ, USA | Baltimore, MD, USA
Candidates must be based in Philadelphia, PA, Baltimore, MD, or Princeton, NJ.
Company Size
1-10
Company Stage
Debt Financing
Total Funding
$102.5M
Headquarters
Santa Cruz, California
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Research presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting shows how the Amplity Health Insights™ Real-World Database enhances understanding of clinical decision-makingLANGHORNE, Pa., June 7, 2024 /PRNewswire/ -- Using point-of-care real-world data to analyze patterns, Amplity Health, a contract sales and medical outsourcing partner, found that biomarker testing for patients with non-small cell lung cancer (NSCLC) in the United States is significantly underutilized. Presented on June 3 at the 2024 ASCO Annual Meeting in Chicago, "Biomarker Testing and Targeted Therapy Use Among Patients With Non-Small Cell Lung Cancer in the United States: An Analysis Using a Physician Notes Real-World Database," highlights critical gaps in testing practices and underscores the need for improved diagnostic strategies.Melanie Jardim, PhD, an Amplity Health executive and principal investigator of the study, shares “Biomarker Testing and Targeted Therapy Use Among Patients with Non-Small Cell Lung Cancer in the United States: An Analysis Using a Physician Notes Real-World Database,” at #ASCO24.By using natural language processing to examine more than 70 million records, this study showed that:A total of 61,018 patients were identified in the Amplity Health Insights ™ Database as having been diagnosed with NSCLC from October 2003 through November 2023™ Database as having been diagnosed with NSCLC from through Of the patients identified in the database as having NSCLC, only 13.4% were recorded as being biomarker testedOf the 6,387 patients with a mutation identified, only approximately 36% received an indicated treatment"Our data further suggest that even when biomarker testing is conducted, and actionable mutations are confirmed, many patients may not be receiving an appropriate targeted therapy," says Melanie Jardim, PhD, an Amplity Health executive and principal investigator of the study."When working with healthcare providers and clients, Amplity's goal is to help remove barriers and address social determinants related to biomarker testing and treatment, ultimately enhancing outcomes across all populations," adds Chris Baker, CEO of Amplity Health.Insights, Amplity's proprietary real-world qualitative database, analyzes over 70 million electronic medical records and effectively uncovers gaps in care. By leveraging data from community settings, combined with ethnicity and SDOH variables, Insights can be used to identify and address social inequities in healthcare. This enables pharmaceutical organizations to better align their strategies to ensure inclusive treatment and access for all patients.About Amplity InsightsAmplity Insights is Amplity Health's proprietary data offering, which provides solutions to clients' most elusive data challenges. By illuminating WHY healthcare practitioners make treatment decisions, our data solutions assist health economics and outcomes research, commercial, clinical, and data analytics teams in biopharma to rapidly move from hypothesis to impact. The mission of Amplity Insights is to maximize the utility of unstructured data by creating easy-to-use, state-of-the-art products and tools to empower leaders to serve patients better.This includes an unparalleled database, the Xplore platform, and the AI-driven search tool, AskX
Earlier this month, Amplity Health announced a merger with medical communications company Lynx.
LANGHORNE, Pa., Feb. 5, 2024 /PRNewswire/ -- Amplity Health, a leading global contract medical and commercial organization, announced today that it has appointed Chris Baker to the position of Chief Executive Officer (CEO), effective immediately. Michael A. Griffith, Amplity founder and long-standing CEO, will transition to the role of Chairman of the Board of Directors as part of a deliberate succession plan. In this capacity, he will continue to support Baker and the leadership team, but with a primary focus on building the visibility and awareness of Amplity in the biopharmaceutical market.Chris Baker joins Amplity Health as Chief Executive Officer."More and more, we are seeing a convergence between medical engagement and commercial engagement," says Griffith. "Chris brings significant leadership experience in large pharma commercial operations, contract research, and data to this role
LANGHORNE, Pa., Feb. 5, 2024 /PRNewswire/ -- Amplity Health, a leading global contract medical and commercial organization, announced today that it has appointed Chris Baker to the position of Chief Executive Officer (CEO), effective immediately. Michael A. Griffith, Amplity founder and long-standing CEO, will transition to the role of Chairman of the Board of Directors as part of a deliberate succession plan. In this capacity, he will continue to support Baker and the leadership team, but with a primary focus on building the visibility and awareness of Amplity in the biopharmaceutical market.Chris Baker joins Amplity Health as Chief Executive Officer."More and more, we are seeing a convergence between medical engagement and commercial engagement," says Griffith. "Chris brings significant leadership experience in large pharma commercial operations, contract research, and data to this role
Survey by AskX delivers real-time, next-level insights with ease — both pre and post drug launchLANGHORNE, Pa., Dec. 6, 2023 /PRNewswire/ -- Contract Medical and Commercial Organization, Amplity Health has released a revolutionary AI-driven next best action solution that provides pharmaceutical and biopharmaceutical companies with an entirely new order of field insights that can be acted upon within the earliest days of a drug's release.The first six weeks of a launch can make or break a drug's future market performance. Traditional surveys and data collection practices can severely limit informed action during a critical time; shortcomings like clunky language and sluggish response times leave pharmaceutical and biopharmaceutical industry leaders lacking important insights while the clock ticks on their new medication's honeymoon period.Now, Amplity Health has completely flipped that script. Amplity's new Survey by AskX platform employs first-of-its-kind AI-powered capabilities that allow leadership to create customized field surveys and explore results using advanced application of generative AI on free-text responses.The Survey by AskX environment is entirely free-text based, meaning leaders can construct surveys and investigate their results in plain speak — without the need for extra time and personnel to make sense of survey findings. The results constitute a dramatic up-leveling in the consistency, punctuality, and value of field insights."Until now, there has never been a way for us to compliantly record the results of discussions between field reps and clinicians in free-text," said Joe Turner, Head of Amplity Insights. "Leaders not only had to poll their teams for anecdotal insights; they had to work to understand the results